| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 7, 2022Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session
Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical Data to be Presented on Parallel-lead,...
-
Sep 1, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...
-
Aug 10, 2022Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-520 for advanced ROS1 positive NSCLC and other solid tumors
Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-520 for advanced ROS1 positive NSCLC and other solid tumors Rapid advancement of pipeline with...
-
Aug 5, 2022Trial in progress poster also to be presented for Phase 1/2 ARROS-1 study of ROS1-selective inhibitor NVL-520
Trial in progress poster also to be presented for Phase 1/2 ARROS-1 study of ROS1-selective inhibitor NVL-520 CAMBRIDGE, Mass., Aug. 5, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a...
-
Aug 3, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...
-
Jul 20, 2022
Darlene Noci, A.L.M. promoted to Chief Development Officer
Benjamin Lane, Ph.D. promoted to Senior Vice President, Technical Operations
Darlene Noci, A.L.M. promoted to Chief Development Officer Benjamin Lane, Ph.D. promoted to Senior Vice President, Technical Operations CAMBRIDGE, Mass., July 20, 2022 /PRNewswire/ -- Nuvalent,...
-
Jul 13, 2022Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC with a compound resistance mutation continues to support potential for best-in-class profile
Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC with a compound resistance mutation continues to support potential for best-in-class profile...
-
Jun 21, 2022
Preliminary dose-escalation data anticipated in second half of 2022 for ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors
First patient dosed in ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors
Preliminary dose-escalation data anticipated in second half of 2022 for ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors...
-
Jun 2, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...
-
May 12, 2022
Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors
On-track for selection of two additional development candidates in 2022
Ended the first quarter of 2022 with $272.7 million in cash, cash equivalents, and marketable securities to support planned operations into 2024
Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors On-track for selection of two additional development candidates in 2022 Ended the first quarter of...
The information in Nuvalent’s press releases is accurate only as of the date of issuance. Nuvalent assumes no duty to update or revise the information contained in the press releases after their original release date.
